Research Overview

A number of clinical trials have demonstrated that it is possible to slow the progression of kidney disease, for example by using converting enzyme inhibitors. What is also clear from these trials is that the rate of progression remains significant despite the optimal therapy currently available. We are currently employing genetics, pharmacogenetic, and mass spectrometry-based proteomic techniques to identify genetic polymorphisms and proteomic patterns that predict the progression of kidney disease and effectiveness of therapy in subjects from the African American Study of Kidney Disease and Hypertension (AASK) Study. Using these techniques we hope to identify patients a risk for progressive renal disease, and new targets for therapeutic interventions.